A	a	O	O
case	case	O	O
of	of	O	O
polymyositis	polymyositis	O	S_disease
in	in	O	O
a	a	O	O
patient	patient	O	O
with	with	O	O
primary	primary	O	B_disease
biliary	biliary	O	B_disease
cirrhosis	cirrhosis	O	I_disease
treated	treated	O	O
with	with	O	O
D-penicillamine	d-penicillamine	S_chemicals	O
.	.	O	O

Although	although	O	O
D-penicillamine	d-penicillamine	S_chemicals	O
has	has	O	O
been	been	O	O
used	used	O	O
for	for	O	O
many	many	O	O
rheumatologic	rheumatologic	O	O
diseases	diseases	O	S_disease
,	,	O	O
toxicity	toxicity	O	O
limits	limits	O	O
its	its	O	O
usefulness	usefulness	O	O
in	in	O	O
many	many	O	O
patients	patients	O	O
.	.	O	O

Polymyositis/dermatomyositis	polymyositis/dermatomyositis	O	O
can	can	O	O
develop	develop	O	O
as	as	O	O
one	one	O	O
of	of	O	O
the	the	O	O
autoimmune	autoimmune	O	O
complications	complications	O	O
of	of	O	O
D-penicillamine	d-penicillamine	S_chemicals	O
treatment	treatment	O	O
,	,	O	O
but	but	O	O
its	its	O	O
exact	exact	O	O
pathogenesis	pathogenesis	O	O
remains	remains	O	O
unclear	unclear	O	O
.	.	O	O

We	we	O	O
report	report	O	O
a	a	O	O
patient	patient	O	O
with	with	O	O
primary	primary	O	B_disease
biliary	biliary	O	B_disease
cirrhosis	cirrhosis	O	I_disease
,	,	O	O
who	who	O	O
developed	developed	O	O
polymyositis	polymyositis	O	S_disease
while	while	O	O
receiving	receiving	O	O
D-penicillamine	d-penicillamine	S_chemicals	O
therapy	therapy	O	O
.	.	O	O

We	we	O	O
described	described	O	O
the	the	O	O
special	special	O	O
clinical	clinical	O	B_disease
course	course	O	I_disease
of	of	O	O
the	the	O	O
patient	patient	O	O
.	.	O	O

Patients	patients	O	O
receiving	receiving	O	O
D-penicillamine	d-penicillamine	S_chemicals	O
therapy	therapy	O	O
should	should	O	O
be	be	O	O
followed	followed	O	O
carefully	carefully	O	O
for	for	O	O
the	the	O	O
development	development	O	O
of	of	O	O
autoimmune	autoimmune	O	O
complications	complications	O	O
like	like	O	O
polymyositis/dermatomyositis	polymyositis/dermatomyositis	O	O
.	.	O	O

